Compare AIRG & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRG | ATNM |
|---|---|---|
| Founded | 1995 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.4M | 45.2M |
| IPO Year | 2016 | N/A |
| Metric | AIRG | ATNM |
|---|---|---|
| Price | $4.37 | $1.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $6.33 | $4.00 |
| AVG Volume (30 Days) | 32.8K | ★ 137.7K |
| Earning Date | 02-26-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $54,737,000.00 | $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $3.00 | $1.03 |
| 52 Week High | $8.47 | $2.41 |
| Indicator | AIRG | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 66.24 | 42.97 |
| Support Level | $3.88 | $1.27 |
| Resistance Level | $4.10 | $1.36 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 78.59 | 26.00 |
Airgain Inc is engaged in providing antenna technologies. These technologies can be used to enable performance wireless networking across devices and markets which include connected homes, enterprises, automotive, and the Internet of Things. It also provides solutions to complex radio frequency, engineering challenges, and improving wireless service that require higher throughput, broad coverage footprint, and carrier-grade quality. Geographically, it derives maximum revenue from North America and also has a presence in China and the Rest of the World. The company products include Antenna Plus: Fleet, M2M, IoT Antennas, Carrier-Class Antenna, Embedded Antennas, and External Dipole Antennas.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.